Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (…

Background & Aims Coronavirus disease 2019 (COVID-19) has placed a significant strain
on national healthcare systems at a critical moment in the context of hepatitis elimination. …

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and
mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting …

Background The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV)
infection as a public health threat by 2030; existing therapies and prophylaxis …

Background The past two decades have seen expansion of childhood vaccination programmes
in low-income and middle-income countries (LMICs). We quantify the health impact of …

Background: Vaccination is one of the most effective public health interventions. We investigate
the impact of vaccination activities for Haemophilus influenzae type b, hepatitis B, human …

Background Hepatitis C virus (HCV) prevalence estimates for adults and high-risk groups
have been widely published, but the disease burden in children is poorly understood. Direct-…

Hepatitis D virus (HDV) infection occurs as a coinfection with hepatitis B and increases the
risk of hepatocellular carcinoma, decompensated cirrhosis, and mortality compared to …

Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease and related
mortality globally. However, most of the infected individuals in the United States remain …

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis,
embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This …